The Dementia with Diabetes market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Dementia with Diabetes market size from 2017 to 2030.The report also covers current Dementia with Diabetes treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Dementia with Diabetes Overview
Dementia is a malady—usually of a chronic or progressive nature—in which there is deterioration in cognitive function (i.e., the ability to process thought). It affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. The impairment in cognitive function is commonly accompanied and occasionally preceded, by deterioration in emotional control, social behavior, or motivation. Dementia develops as a result of a complex interplay of clinical and biological factors and is beset by multiple underlying pathological features. People with type II diabetes represent a substantial risk group for cognitive impairment and dementia caused by both Alzheimer’s disease dementia and vascular brain injury. Furthermore, type II diabetes increases the risk of mortality in patients who already have dementia, suggesting that targeted intervention at any point may improve health outcomes.
Request free sample copy- https://www.delveinsight.com/sample-request/dementia-with-diabetes-market-forecast
List of regions covered in the report
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
List of companies involved in the report
- vTv Therapeutics
- Novo Nordisk
- And many others
Dementia with Diabetes Diagnosis
Self-treatment is encouraged for people with diabetes, so diagnosing dementia in people who already have diabetes will lead to difficulties with self-management and adherence with medication, including the safe administration of insulin injections.
There are several simple screening tests for dementia, including the Mini-Cog test, which has 83% accuracy and takes about 3 min to perform. It is essential to check hearing and sight is intact when assessing for dementia. However, a formal, comprehensive assessment by a specialist memory assessment service is always required to diagnose dementia, with other investigations such as blood tests for thyroid function, brain scan and EEG.
Dementia with Diabetes Treatment
Currently, there are nine classes of orally available pharmacological agents to treat Type II diabetes: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, and 9) sodium-glucose transport protein 2 (SGLT2) inhibitors.
Further, the treatment regimen for Dementia with Diabetes includes non-insulin therapy (Metformin, Thiazolidinedione, Sulfonylureas Meglitinides, Dipeptidyl peptidase-4 inhibitors and Sodium-glucose cotransporter-2 (SGLT-2)), and insulin therapy. The latter is the best option for managing glycemia in patients with diabetes, optimally; however, its use in patients with dementia must be carefully reviewed and assessed. At present, little evidence suggests that specific treatments in diabetes can improve cognitive function.
Dementia with Diabetes Emerging Drugs
- Azeliragon (TTP488): vTv Therapeutics
- Victoza (liraglutide): Novo Nordisk
- And many others
Dementia with Diabetes Market Outlook
The current treatment regimen majorly includes non-insulin therapy (Metformin, Thiazolidinedione, Sulfonylureas, Meglitinides, Dipeptidyl peptidase-4 inhibitors and Sodium-glucose cotransporter-2 (SGLT-2), alpha glucosidase inhibitors, and others) and insulin therapy. The former therapy is recommended if the optimal glycemic goals are not met. The use of the therapy once-daily basal insulin in combination with a non-insulin agent can be used. This is a low-complexity regimen with a relatively lower risk of hypoglycemia compared with regimens using multiple insulin doses. Oral antidiabetic drugs are preferred in the initial stages of the onset of the disease. Moreover, insulin therapy is recommended when the patient is resistant to drugs. Other potential therapies that are undergoing research programmes for different molecule includes Victoza, Bydureon, Jardiance, Lixisenatide, Sitagliptin, Vildagliptin, and others.
Dementia with Diabetes Market Insights
Dementia is a syndrome – usually of a chronic or progressive nature – in which there is deterioration in cognitive function (i.e., the ability to process thought). It affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. The impairment in cognitive function is commonly accompanied, and occasionally preceded, by deterioration in emotional control, social behavior, or motivation.
Dementia with Diabetes Market Report Scope
- The report covers the descriptive overview of Dementia with Diabetes, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the Dementia with Diabetes epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Dementia with Diabetes is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of Dementia with Diabetes market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Dementia with Diabetes market.
Request free sample copy- https://www.delveinsight.com/sample-request/dementia-with-diabetes-market-forecast
Table of Content
1 Key Insights
2 Executive Summary
3 SWOT Analysis
4 Dementia with Diabetes Market Overview at a Glance
5 Disease Background and Overview: Dementia with Diabetes
6 Recognized Establishments
7 Epidemiology and Patient Population
8 7MM Epidemiology of Dementia with Diabetes
9 Treatment
10 Endocrine Society’s Clinical Practice Guideline offers diagnosis and Treatment Recommendations of Diabetes in Older Adults
11 Unmet Needs
12 Emerging Drugs
13 Dementia with Diabetes: 7 Major Market Analysis
14 Conjoint Analysis
15 7MM Market Outlook
16 United States Market Size
17 EU-5 Market Size
18 Access and Reimbursement Overview: Dementia and Diabetes
19 Case Reports
20 Market Drivers
21 Market Barriers
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight
Dementia and Diabetes Market Report Highlights
- Dementia with Diabetes market is anticipated to increase at a CAGR of 4.30% for the study period 2017–2030.
- The United States accounted for more than half (73 %) of the market share in the 7MM.
- In the coming years, Dementia with Diabetes market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Dementia with Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Dementia with Diabetes. Launch of emerging therapies will significantly impact the Dementia with Diabetes market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Dementia with Diabetes.
- To understand the future market competition in the Dementia with Diabetes market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Dementia with Diabetes in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for Dementia with Diabetes market.
- To understand the future market competition in the Dementia with Diabetes market.
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
